Cite
Dosch J, Ziemke E, Wan S, et al. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget. 2017;8(39):65090-65099doi: 10.18632/oncotarget.17780.
Dosch, J., Ziemke, E., Wan, S., Luker, K., Welling, T., Hardiman, K., Fearon, E., Thomas, S., Flynn, M., Rios-Doria, J., Hollingsworth, R., Herbst, R., Hurt, E., & Sebolt-Leopold, J. (2017). Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget, 8(39), 65090-65099. https://doi.org/10.18632/oncotarget.17780
Dosch, Joseph, et al. "Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency." Oncotarget vol. 8,39 (2017): 65090-65099. doi: https://doi.org/10.18632/oncotarget.17780
Dosch J, Ziemke E, Wan S, Luker K, Welling T, Hardiman K, Fearon E, Thomas S, Flynn M, Rios-Doria J, Hollingsworth R, Herbst R, Hurt E, Sebolt-Leopold J. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget. 2017 May 10;8(39):65090-65099. doi: 10.18632/oncotarget.17780. eCollection 2017 Sep 12. PMID: 29029414; PMCID: PMC5630314.
Copy
Download .nbib